TABLE 2

BMD Annual Growth Rate (g/cm2 per year) by Corticosteroid Use and Smoking Status Stratified According to Gender

Variable at Last Follow-up VisitBoysGirlsP, Gender × Variable Interaction
nRateaPnRateaP
Cumulative OCS courses
    01080.052Reference660.052ReferenceReference
    >0 and <52680.049.12001680.053.7300.0800
    ≥51550.046.00091120.049.2900.0800
    Test for trend.0002.2300.1100
Cumulative ICS, mg
    01890.051Reference1180.052ReferenceReference
    1–4371260.046.0040840.052.9400.0400
    ≥438b2160.048.03001440.051.5400.5800
    Test for trend.0500.4500.6400
Passive smoking.9100.3500.7500
    No3180.0491780.051
    Yes2130.0491680.052
Active smoking.8100.4200.8900
    No5030.0493200.051
    Yes280.050260.054
  • a Adjusted for all variables in table; race and BMD at baseline; and the following variables with value at last follow-up visit: age, Tanner stage (genital stage for boys and breast stage for girls), machine type, fan-beam type, BMI-for-age percentile, and height. Rate was defined as (BMD at last follow-up − BMD at baseline visit)/years since baseline; BMD measurements were standardized to Hologic with fan beam by using the following formulas: Hologic BMD = 0.885*Lunar BMD; fan-beam BMD = pencil-beam BMD + .0549 if height ≥1.40 m.

  • b The amount of a full dose (400 μg/day) of budesonide in the CAMP trial for 3 years was 438 mg; patients in the 1- to 437-mg category had a median cumulative ICS amount of 153 mg, whereas patients in the ≥438-mg category had a median dose of 690 mg.